Skin Cancer: Molecular Biomarker for Diagnosis, Prognosis, Prevention, and Targeted Therapy

Pandey, Sachchida Nand

doi:10.1007/978-981-16-0364-8_7

Cited by 1 publication

(2 citation statements)

References 234 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite many new treatment options for advanced melanoma today, the response to treatment differs in patients, and many patients may develop resistance to therapy or adverse effects [ 13 – 15 ]. Diagnostic and prognostic biomarkers are increasingly important in melanoma treatment so that they may have improved survival and treatment [ 16 – 18 ]. In clinical settings, proper prognostication of patients is necessary to select the suitable treatment plan for each patient to maximize efficacy and decrease the expenses and adverse effects of the treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Although many new genomic and protein markers including the S-100b and Lactate dehydrogenase (LDH) proteins have been suggested for advanced melanoma prognostication, no feasible lab tests are available today to stratify high-risk patients with high accuracy in clinical settings [ 19 , 20 ]. New prognostic markers and therapeutic targets for both melanoma and NMSCs are urgently needed to optimize patient management and decrease the morbidity and mortality of the disease [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients

et al. 2023

View full text Add to dashboard Cite

Background Talin-1 as a component of multi-protein adhesion complexes plays a role in tumor formation and migration in various malignancies. This study investigated Talin-1 in protein levels as a potential prognosis biomarker in skin tumors. Methods Talin-1 was evaluated in 106 skin cancer (33 melanomas and 73 non-melanomas skin cancer (NMSC)) and 11 normal skin formalin-fixed paraffin-embedded (FFPE) tissue samples using immunohistochemical technique on tissue microarrays (TMAs). The association between the expression of Talin-1 and clinicopathological parameters, as well as survival outcomes, were assessed. Results Our findings from data minings through bioinformatics tools indicated dysregulation of Talin-1 in mRNA levels for skin cancer samples. In addition, there was a statistically significant difference in Talin-1 expression in terms of intensity of staining, percentage of positive tumor cells, and H-score in melanoma tissues compared to NMSC (P = 0.001, P < 0.001, and P < 0.001, respectively). Moreover, high cytoplasmic expression of Talin-1 was found to be associated with significantly advanced stages (P = 0.024), lymphovascular invasion (P = 0.023), and recurrence (P = 0.006) in melanoma cancer tissues. Our results on NMSC showed a statistically significant association between high intensity of staining and the poor differentiation (P = 0.044). No significant associations were observed between Talin-1 expression levels and survival outcomes of melanoma and NMSC patients. Conclusion Our observations showed that higher expression of Talin1 in protein level may be significantly associated with more aggressive tumor behavior and advanced disease in patients with skin cancer. However, further studies are required to find the mechanism of action of Talin-1 in skin cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%